Day One Biopharmaceuticals Inc (DAWN) — Cash Flow-to-Debt Ratio
Day One Biopharmaceuticals Inc (DAWN) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of $-5.80 Million could theoretically repay 0% of its total liabilities ($62.91 Million) in one year. See financial agility of Day One Biopharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Day One Biopharmaceuticals Inc Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Day One Biopharmaceuticals Inc across 6 annual periods. For the full cash flow conversion analysis, see DAWN cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Day One Biopharmaceuticals Inc (2019–2024)
Year-by-year debt coverage analysis for Day One Biopharmaceuticals Inc. Check Day One Biopharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.98x | $-78.11 Million | $80.04 Million | ▲ +80.4% |
| 2023 | -4.98x | $-146.85 Million | $29.51 Million | ▲ +22.9% |
| 2022 | -6.45x | $-109.87 Million | $17.02 Million | ▼ -15.3% |
| 2021 | -5.60x | $-48.54 Million | $8.67 Million | ▲ +8.7% |
| 2020 | -6.13x | $-13.49 Million | $2.20 Million | ▼ -4316.9% |
| 2019 | -0.14x | $-4.51 Million | $32.52 Million | — |